Search Results 801-810 of 17550 for Assay
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease (CAMPERR). Rochester, Minn. The purpose of this ...
... assay performed on NanoString's nCounter® Dx Analysis System as assessed by Central Pathology. (ABC type subjects are reported by the GEP assay as eligible ...
Challenging search for ovarian cancer early detection assay appears hopeful. In a clinical pilot study, an 11-MDM ovarian cancer panel, developed at Mayo ...
... assay; MSLN expression score using Ventana immunohistochemistry (IHC) SP74 assay; Phase I only: In addition 5- 30% tumor cells and 1, 2, or 3+ MSLN score ...
... assay using the established threshold of the chosen assay (i.e., PCR, NGS, etc.). No use or disclosure outside AbbVie is permitted without prior written ...
The purpose of this study is to evaluate the clinical performance of the Aptima CMV Quant assay on the Panther system in ethylenediaminetetraacetic acid (EDTA) ...
The test includes CSF assays for beta-amyloid, total tau and phosphorylated tau. Although beta-amyloid can be detected with positron emission tomography ...
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease (CAMPERR) Rochester, MN. The purpose of this ...
Cohort 1 includes blood collections for in vitro studies which are a component of NIH-funded Project 3 within the Mayo Clinic ... cfDNA Assay Prospective ...
... assays within 3 months prior to randomization. Key Exclusion Criteria: * Transplant: Blood type (ABO)-incompatible transplant. * History of multiple organ ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.